Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 21

Trial Status

Other3

Role Distribution

Principal Investigator2
Other Roles1
PI Rate67%

Activity Timeline

Clinical Trials (3)

NCT05025488Phase 1Active Not Recruiting
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Essential ThrombocythemiaMPNMyelofibrosis
PrincipalinvestigatorStart date: 2023-04-04
NCT02469974Not ApplicableWithdrawn
Ruxolitinib in Combination With Autotransplant
MFMyelofibrosis
Principalinvestigator
NCT07872709Phase 2Not Yet Recruiting
Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
Chric Phase MPNMPN - Accelerated or Blast PhaseMyelofibrosis
Studychair

Research Network

Collaboration Network

29 collaborators·30 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

John Mascarenhas, MD

Icahn School of Medicine at Mount Sinai

Moderately Similar
16 trials

Shared therapeutic areas:

Primary MyelofibrosisThrombocythemia, EssentialChric Phase MPN+1 more

Worked with same sponsors:

Incyte CorporationJohn Mascarenhas+2 more
Collaborated on 1 trial
Similarity Score44%

Shivani V Handa, MD

Ohio State University

Moderately Similar
1 trials

Shared therapeutic areas:

Chric Phase MPNMPN - Accelerated or Blast PhasePrimary Myelofibrosis

Worked with same sponsors:

John MascarenhasNational Cancer Institute (NCI)+1 more
Collaborated on 1 trial
Similarity Score34%

Nina Bhardwaj, MD, PhD

Icahn School of Medicine at Mount Sinai

Moderately Similar
8 trials

Shared therapeutic areas:

Thrombocythemia, EssentialMPNPrimary Myelofibrosis

Worked with same sponsors:

Marina KremyanskayaNational Cancer Institute (NCI)
Collaborated on 1 trial
Similarity Score34%

Camelia Iancu-Rubin, PhD

Icahn School of Medicine at Mount Sinai

Moderately Similar
1 trials

Shared therapeutic areas:

Thrombocythemia, EssentialMPNPrimary Myelofibrosis

Worked with same sponsors:

Marina Kremyanskaya
Collaborated on 1 trial
Similarity Score34%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Primary MyelofibrosisThrombocythemia, Essential

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Rami Komrokji, MD

H. Lee Moffitt Cancer Center and Research Institute

Related
5 trials

Shared therapeutic areas:

Thrombocythemia, EssentialPrimary Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Ronald Hoffman, MD

Icahn School of Medicine at Mount Sinai

Related
10 trials

Shared therapeutic areas:

Primary MyelofibrosisThrombocythemia, Essential

Worked with same sponsors:

Incyte CorporationJohn Mascarenhas+1 more
Similarity Score10%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Thrombocythemia, EssentialPrimary Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Brenda Sandmaier

Fred Hutch/University of Washington Cancer Consortium

Related
7 trials

Shared therapeutic areas:

Thrombocythemia, EssentialPrimary Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Martha Wadleigh, MD

Dana-Farber Cancer Institute

Related
3 trials

Shared therapeutic areas:

Primary MyelofibrosisThrombocythemia, Essential

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT05025488Phase 1PrincipalInvestigator

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Essential ThrombocythemiaMPNMyelofibrosis
Active Not Recruiting
NCT02469974Not ApplicablePrincipalInvestigator

Ruxolitinib in Combination With Autotransplant

MFMyelofibrosis
Withdrawn
NCT07872709Phase 2StudyChair

Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

Chric Phase MPNMPN - Accelerated or Blast PhaseMyelofibrosis
Not Yet Recruiting

All 3 trials loaded